Wei-Xin Chin

Wei-Xin Chin

Auto-generated profile, based on publicly available information

Wei-Xin Chin

Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University Health System, National University of Singapore, MD4 Level 5, 5 Science Drive 2, Singapore, 117597, Singapore

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2016 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
YSYouichi Suzuki
Youichi Suzuki
WCWei-Xin Chin
Wei-Xin Chin
QHQi'EN Han
Qi'EN Han
KIKoji Ichiyama
Koji Ichiyama
CLChing Hua Lee
Ching Hua Lee
NYNaoki Yamamoto
Naoki Yamamoto
Dengue virus (DENV) is one of the most important arthropod-borne pathogens that cause life-threatening diseases in humans. However, no vaccine or specific antiviral is available for dengue. As seen in other RNA viruses, the innate immune system plays a key role in controlling DENV infection and disease outcome. Although the interferon (IFN) response, which is central to host protective immunity, has been reported to limit DENV replication, the molecular details of how DENV infection is modulated by IFN treatment are elusive. In this study, by employing a gain-of-function screen using a type I IFN-treated cell-derived cDNA library, we identified a previously uncharacterized gene, C19orf66, as an IFN-stimulated gene (ISG) that inhibits DENV replication, which we named Repressor of yield of DENV (RyDEN). Overexpression and gene knockdown experiments revealed that expression of RyDEN confers resistance to all serotypes of DENV in human cells. RyDEN expression also limited the replication of hepatitis C virus, Kunjin virus, Chikungunya virus, herpes simplex virus type 1, and human adenovirus. Importantly, RyDEN was considered to be a crucial effector molecule in the IFN-mediated anti-DENV response. When affinity purification-mass spectrometry analysis was performed, RyDEN was revealed to form a complex with cellular mRNA-binding proteins, poly(A)-binding protein cytoplasmic 1 (PABPC1), and La motif-related protein 1 (LARP1). Interestingly, PABPC1 and LARP1 were found to be positive modulators of DENV replication. Since RyDEN influenced intracellular events on DENV replication and, suppression of protein synthesis from DENV-based reporter construct RNA was also observed in RyDEN-expressing cells, our data suggest that RyDEN is likely to interfere with the translation of DENV via interaction with viral RNA and cellular mRNA-binding proteins, resulting in the inhibition of virus replication in infected cells. Dengue is the most common arthropod-borne viral infection and is spreading to new areas every year. Its causative agent, dengue virus (DENV), has immunologically distinct serotypes that increase the risk of life-threatening diseases such as dengue hemorrhagic fever. However, an effective medication for dengue has not yet been established. There is, therefore, an urgent need to develop new antivirals and vaccines against DENV. Here, we have characterized C19orf66, named Repressor of yield of DENV (RyDEN), as a cellular gene that inhibits the replication of all DENV serotypes. The expression of RyDEN was found to be upregulated by interferon (IFN) treatment and played a critical role in the IFN-mediated anti-DENV response. We also found that RyDEN was likely to block the protein translation of DENV RNA through its association with cellular mRNA-binding proteins and viral RNA. Intriguingly, replication of several other viruses, such as hepatitis C virus, Kunjin virus, and Chikungunya virus, was also limited by RyDEN expression. Thus, this study describes a novel mechanism of an IFN-inducible inhibitory factor for DENV and provides the basis for future development of broad-spectrum antivirals against infectious viral diseases, including dengue.

25 April 2013 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
KIKoji Ichiyama
Koji Ichiyama
SRSindhoora Bhargavi Gopala Reddy
Sindhoora Bhargavi Gopala Reddy
LZLi Feng Zhang
Li Feng Zhang
WCWei Xin Chin
Wei Xin Chin
TMTegshi Muschin
Tegshi Muschin
NYNaoki Yamamoto
Naoki Yamamoto
Curdlan sulfate (CRDS), a sulfated 1→3-β-D glucan, previously shown to be a potent HIV entry inhibitor, is characterized in this study as a potent inhibitor of the Dengue virus (DENV). CRDS was identified by in silico blind docking studies to exhibit binding potential to the envelope (E) protein of the DENV. CRDS was shown to inhibit the DENV replication very efficiently in different cells in vitro. Minimal effective concentration of CRDS was as low as 0.1 µg/mL in LLC-MK2 cells, and toxicity was observed only at concentrations over 10 mg/mL. CRDS can also inhibit DENV-1, 3, and 4 efficiently. CRDS did not inhibit the replication of DENV subgenomic replicon. Time of addition experiments demonstrated that the compound not only inhibited viral infection at the host cell binding step, but also at an early post-attachment step of entry (membrane fusion). The direct binding of CRDS to DENV was suggested by an evident reduction in the viral titers after interaction of the virus with CRDS following an ultrafiltration device separation, as well as after virus adsorption to an alkyl CRDS-coated membrane filter. The electron microscopic features also showed that CRDS interacted directly with the viral envelope, and caused changes to the viral surface. CRDS also potently inhibited DENV infection in DC-SIGN expressing cells as well as the antibody-dependent enhancement of DENV-2 infection. Based on these data, a probable binding model of CRDS to DENV E protein was constructed by a flexible receptor and ligand docking study. The binding site of CRDS was predicted to be at the interface between domains II and III of E protein dimer, which is unique to this compound, and is apparently different from the β-OG binding site. Since CRDS has already been tested in humans without serious side effects, its clinical application can be considered. There is no specific approved antiviral and vaccine for treatment or prevention of dengue, an acute mosquito-transmitted viral disease that affects more than 50 million people each year. Dengue virus (DENV) entry is a critical step that establishes the infection and enables virus replication. Curdlan sulfate (CRDS) is known to inhibit the entry and propagation of HIV-1 in the laboratory. Here we applied a computational binding site identification strategy, which suggested that CRDS could be a probable entry inhibitor of the viral surface E protein. CRDS potently blocked DENV infection at an early stage of the virus lifecycle in vitro. In addition, CRDS prevented antibody dependent enhancement, which is considered to be one of the most important clinical observations in DENV-infected patients. CRDS shows a favorable selectivity index against all serotypes of DENV. Further computational docking indicates that the compound binds to a pocket on the DENV E protein. Since CRDS has already been tested in humans without serious side effects, it can be a good candidate for clinical application.

1 December 2020 in Antiviral Research
Verified
Journal Article
Closed access
MLMarcus Wing Choy Loe
Marcus Wing Choy Loe
EHErwei Hao
Erwei Hao
MCMeiling Chen
Meiling Chen
CLCong Li
Cong Li
RLRegina Ching Hua Lee
Regina Ching Hua Lee
Justin Jang Hann CHUJustin Jang Hann CHU
Justin Jang Hann CHU

1 August 2018 in Biochemical Pharmacology
Verified
Journal Article
Closed access
SRSindhoora Bhargavi Gopala Reddy
Sindhoora Bhargavi Gopala Reddy
WCWei-Xin Chin
Wei-Xin Chin
NSNanjunda Swamy Shivananju
Nanjunda Swamy Shivananju

1 November 2019 in Antiviral Research
Verified
Journal Article
Closed access
JLJing Kai Lee
Jing Kai Lee
JCJane Li Min Chui
Jane Li Min Chui
RLRegina Ching Hua Lee
Regina Ching Hua Lee
HKHao Yuin Kong
Hao Yuin Kong
WCWei-Xin Chin
Wei-Xin Chin
Justin Jang Hann CHUJustin Jang Hann CHU
Justin Jang Hann CHU

1 September 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
BTBeng Hui Tan
Beng Hui Tan
YSYasutsugu Suzuki
Yasutsugu Suzuki
HTHirotaka Takahashi
Hirotaka Takahashi
PYPamela Ho Rui Ying
Pamela Ho Rui Ying
CTChikako Takahashi
Chikako Takahashi
YSYouichi Suzuki
Youichi Suzuki
Integration, one of the hallmarks of retrovirus replication, is mediated by a nucleoprotein complex called the preintegration complex (PIC), in which viral DNA is associated with many protein components that are required for completion of the early phase of infection. A striking feature of the PIC is its powerful integration activity in vitro. The PICs from a freshly isolated cytoplasmic extract of infected cells are able to insert viral DNA into exogenously added target DNA in vitro. Therefore, a PIC-based in vitro assay is a reliable system for assessing protein factors influencing retroviral integration. In this study, we applied a microtiter plate-based in vitro assay to a screening study using a protein library that was produced by the wheat germ cell-free protein synthesis system. Using a library of human E3 ubiquitin ligases, we identified RFPL3 as a potential stimulator of human immunodeficiency virus, type 1 (HIV-1) PIC integration activity in vitro. This enhancement of PIC activity by RFPL3 was likely to be attributed to its N-terminal RING domain. To further understand the functional role of RFPL3 in HIV infection, we created a human cell line overexpressing RFPL3. Immunoprecipitation analysis revealed that RFPL3 was associated with the human immunodeficiency virus, type 1 PICs in infected cells. More importantly, single-round HIV-1 infection was enhanced significantly by RFPL3 expression. Our proteomic approach displays an advantage in the identification of new cellular proteins affecting the integration activity of the PIC and, therefore, contributes to the understanding of functional interaction between retroviral integration complexes and host factors.